[Chronic myeloid leukemia: up-to-date management].
Kazutaka
K
Nakayama
Koiti
K
Inokuchi
D001549:Benzamides / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D000069439:Dasatinib; D055808:Drug Discovery / Q000639:trends; D016903:Drug Monitoring; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000145:classification / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D055118:Medication Adherence; D058990:Molecular Targeted Therapy; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects
D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib; D000069439:Dasatinib